Medipharm Labs Corp T.LABS

Alternate Symbol(s): MEDIF

Healthcare Cannabis

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.

TSX:LABS - Post by User

Medipharm Labs Corp > Q3 - Germany WTF

<< Previous

Bullboard Posts

Next >>

Comment by okgonowon Nov 14, 2024 9:40am

60 Views

Post# 36312480

RE:RE:RE:Q3 - Germany WTF

i dont think its as bad a you think it is actually have a closer look at the tables they put out there are some omne time codts they put on the spreadsheet

im no accountant

	Three months ended
	September 30, 2024	June 30, 2024	March 31, 2024	December 31, 2023
	$'000s	$'000s	$'000s	$'000s
Net operating loss	(2,708)	(2,573)	(3,725)	(2,935)
Adjusted for:	-	-	-	-
Share-based compensation expense	160	576	895	306
Depreciation and amortization	518	731	790	717
Restructuring related severance expenses	87	305	755	335
Impairment loss on remeasurement of assets held for sale	113	77	-	23
Gain on disposition of assets	-	(20)	(276)	(174)
Early lease termination cost	-	-	44	-
Incremental cost of cannabis inventory acquired in a business combination ⁽¹⁾	110	162	327	372
Terminal costs for closed facility ⁽²⁾	-	95	323	-
One-off derecognition of liabilities	-	-	(130)	-
Write down of inventories ⁽³⁾	27	60	-	-
Fair value adjustments in gross profit	519	170	48	(223)
HST reassessment ⁽⁴⁾	153	240	-	-
Payroll tax assessment	-	42	-	-
Miscellaneous	-	11	-	-
Transaction costs ⁽⁵⁾	278	-	-	-
Adjusted EBITDA	(743)	(124)	(949)	(1,579)

	Three months ended
	September 30, 2023	June 30, 2023	March 31, 2023	December 31, 2022
	$'000s	$'000s	$'000s	$'000s
Net operating loss	(4,355)	(7,629)	(3,333)	(6,390)
Adjusted for:
Share-based compensation expense	386	588	747	1,390
Depreciation and amortization	617	692	490	540
Restructuring related severance expenses	273	1,695	-	-
Impairment loss on remeasurement of assets held for sale	17	-	-	13
Transaction costs ⁽⁴⁾	46	304	533	813
Recovery of impaired receivables ⁽¹⁾	-	(464)	(1,546)	-
Write down of inventories ⁽²⁾	168	1,036	-	-
Incremental cost of cannabis inventory acquired in a business combination ⁽³⁾	2,055	-	-	-
Fair value adjustments in gross profit	(1,553)	588	-	-
Other tax recovery	-	(1)	-	-
Miscellaneous	-	-	19	-
Adjusted EBITDA	(2,346)	(3,191)	(3,090)	(3,634)